Parkinson’s disease studied using PET
Positron emission tomography makes it possible to measure quantitatively certain aspects of regional brain tissue energy metabolism and dopaminergic neurotransmitter activity in vivo in man. It has been shown that this method can be applied in the study of pathophysiology of Parkinson’s disease and other conditions. Striatal influx of the radiolabelled tracer L-18F-fluoro-dopa is related to the clinical severity of the disease. A pre-clinical diagnosis of Parkinson’s disease should in principle be possible, although no PET studies with this particular aim have been undertaken yet.
Combination with a tracer for the dopamine D2 receptors may help in making the diagnosis. In Parkinson’s disease dopamine turnover is markedly decreased while the density of dopamine D2 receptors is essentially unchanged compared to age-matched controls. On the other hand in neurodegenerative conditions accompanied by parkinsonism both “pre-” and “post-synaptic” binding of tracers seem to be impaired.
KeywordsPositron Emission Tomography Positron Emission Tomography Study Positron Emission Tomography Scanning Striatal Dopamine Nigrostriatal Dopaminergic Pathway
Unable to display preview. Download preview PDF.
- Aquilonius SM, Bergström K, Eckernäs SA, Hartvig P, Leenders KL, Lundqvist H, Antoni G, Gee A, Rimland A, Uhlin J, Lângström B (1987) In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand 76: 283–287PubMedCrossRefGoogle Scholar
- Baron JC, Maziere B, Loc’h C, Sgouropoulos P, Bonnet AM, Agid Y (1985) Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet ii: 1163–1164Google Scholar
- Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) (3 H)spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99: 167–175Google Scholar
- Eckernäs SA, Aquilonius SM, Hartvig P, Hägglund J, Jundgvist H, Nâgren K, Lângström B (1987) Positron emission tomography (PET) in the study of dopamine receptors in the primate brain: evaluation of a kinetic model using 11C-N-methyl-spiperone. Acta Neurol Scand 75: 168–178PubMedCrossRefGoogle Scholar
- Hägglund J, Aquilonius SM, Eckernäs, SA, Hartvig P, Lundquist H, Gull-berg P, Lângström B (1987) Dopamine receptor properties in Parkinson’s disease and Huntington’s chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol Scand 75: 87–94PubMedCrossRefGoogle Scholar
- Leenders KL, Frackowiak RJS, Quinn N, Marsden CD (1986 a) Brain energy metabolism and dopaminergic function in Huntington’s disease measured in vivo using positron emission tomography. Movement Disorders 1: 69–77Google Scholar
- Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD (1986 b) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatr 49: 853–856Google Scholar
- Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RSJ (1986 c) Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20: 258–262 Google Scholar
- Leenders KL (1987) Parkinson’s disease. Clinical and experimental advances. J Libbey, London Paris, pp 21–32Google Scholar
- Leenders KL, Aquilonius SM, Bergstr?m K, Bjurling P, Crossman AR, Eckern?s SA, Gee AG, Hartvig P, Lundqvist H, L?ngstr?m B, Rimland A, Tedroff J (1988 a) Unilateral MPTP lesion in a Rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Research 445: 61–67Google Scholar
- Leenders KL, Frackowiak RJS, Lees AJ (1988 b) Steele-Richardson-Olszewski syndrome: brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 111: 615–630Google Scholar
- Phelps ME, Mazziotta JC, Schelbert HR (eds) (1986) Positron emission tomography and autoradiography. Principles and applications for the brain and heart. Raven Press, New YorkGoogle Scholar
- Slater P, Crossman AR (1984) Nomifensine. A pharmacological and clinical profile. The Royal Society of Medicine, London, pp 15–19Google Scholar